XIDX
PEHA
Market cap15mUSD
Nov 12, Last price
326.00IDR
Name
Phapros Tbk PT
Chart & performance
P/E
9.77
P/S
0.29
EPS
33.37
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-0.82%
Revenues
940.88b
+26.34%
Net income
28.03b
P
CFO
70.98b
-49.76%
Dividend
Jun 23, 20265.01 IDR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Phapros, Tbk is a prominent Indonesian company operating within the pharmaceutical and healthcare sectors. Its operations are broadly categorized into four key divisions: Over-the-Counter (OTC) products, Ethical drugs, Generic drug manufacturing, and Toll Manufacturing services. The company's OTC offerings feature well-known brands such as Antimo Anak, Livron B Plek, Noza, Hemorogard, and Bioron. In addition to supplying generic medications to government institutions and hospitals, PT Phapros also serves as a contract manufacturer for other pharmaceutical companies and provides various medical devices. Established in 1954 with its headquarters located in Jakarta, Indonesia, the company further extends its market reach by exporting products internationally. PT Phapros, Tbk functions as a subsidiary under the umbrella of PT Kimia Farma (Persero) Tbk.
Key people
Johanes Nanang Marjianto
President Commissioner · since 2018
Barokah Sri Utami
President Director · since 2016
Heru Marsono
Director of Finance · since 2016
Chairani Harahap
Director of Marketing · since 2016
Fransetya Hasudungan Hutabarat
Director of Human Resources and General · since 2018
Director of Production · since 2016
Zahmilia Akbar
Corporate Secretary
Tumpal M. Sihombing
Corporate Secretary
Masrizal Achmad Syarief
Commissioner · since 2008
Zainal Abidin
Independent Commissioner · since 2018
Fasli Jalal
Independent Commissioner · since 2014
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||